A new era of
human potential.
Why Longevity?
Research pursuits to help people live healthier, happier lives is accelerating at an unprecedented pace. New anti-obesity drugs are the most recent therapies to offer promise for a range of chronic diseases, including diabetes, heart disease, neurological disorders and more. Biolexis is committed to advancing this movement honorably and with the backbone of scientific rigor.
Built on scientific principles
Biolexis is a pioneering biotechnology company dedicated to rapidly accelerating the potential of human longevity.
Evidence based approach
Our team of world-renowned scientists is at the forefront of breakthroughs in oral small molecule drug discovery, and reducing the impact of metabolic and related diseases.
Phenomenal market growth
Through cutting-edge research and development, we aim to overcome the impact of disease as humans age and extend healthy lifespans for individuals.
The need is real
-
Obesity is the beginning
The World Obesity Federation predicts that 51% of the world - more than 4 billion people - will be obese or overweight within the next 12 years. -
The diabetes threat
In the United States alone, 4 in 10 are obese, and 1 in 10 are diabetic, 90-95% of whom are Type 2, according to the Centers for Disease Control and Prevention. -
Reduced costs
The ability to live healthier lives translates to trillions of dollars saved globally on end of life and ‘sick care’.
The Biolexis opportunity
-
Chronic diseases
Longevity drugs based on metabolic and chronic inflammatory solutions can lead to better treatments for heart disease, cancer, and dementia. -
Happier lifespans
Current health expectations leave many feeling they will not have the opportunity to live to their full potential and want more time to experience life. -
The evolution starts here
We have an opportunity to address this immense need by providing clinically effective, easily administered, and economically viable treatments that improve the lives of these patients.
Investing in human longevity. A metabolic revolution.
What Began with Anti-Obesity Drugs Inspired a Vision for More
Numerous companies are developing products and acquiring others to capture more of the estimated $100 billion market for therapies that target the GLP-1 receptor system.
Biolexis is developing multiple oral small molecules that target GLP-1 in a unique manner while reducing the side effects of currently approved drugs and many in development. Also in our pipeline are AMPK activators (AMP-activated protein kinase), an additional target for obesity, overall health, and longevity, as well as mTORC and TNIK inhibitors.
Biolexis will bring three anti-obesity drugs into the clinic in 2025. Over the long-term, Biolexis seeks to broaden its portfolio to target broader longevity-focused therapies addressing heart disease, diabetes, and potentially dementia.